Abstract:Objective: This study aimed to explore both impairments in attention function in patients with major depressive disorder (MDD) and the efficacy of escitalopram monotherapy or combination therapy with agomelatine. Methods: A total of 54 patients with MDD and 46 healthy controls (HCs) were included. Patients were treated with escitalopram for 12 weeks; those who presented with severe sleep impairments were also given agomelatine. Participants were evaluated using the Attention Network Test (ANT), which included tests of alerting, orienting, and executive control networks. Concentration, instantaneous memory, and resistance to information interference were tested using the digit span test, and the logical memory test (LMT) was used to evaluate abstract logical thinking. The Hamilton Depression Rating Scale−17 items, Hamilton Anxiety Rating Scale, and Pittsburgh Sleep Quality Index were used to assess depression, anxiety, and sleep quality, respectively. Patients with MDD were assessed at the end of weeks 0, 4, 8, and 12. HCs were assessed once at baseline. Results: Compared with HCs, patients with MDD showed significantly different alerting, orienting, and executive control functions of attention networks. Treatment with escitalopram alone or combined with agomelatine significantly improved LMT scores at the end of weeks 4, 8, and 12 and restored scores to the level of HCs at the end of week 8. Total Toronto Hospital Test of Alertness scores in patients with MDD increased significantly after 4 weeks of treatment. The ANT executive control reaction time in patients with MDD decreased significantly after 4 weeks of treatment, with this decrease lasting until the end of week 12, but scores did not return to the levels of HCs. Combined treatment with escitalopram and agomelatine led to more improvement in ANT orienting reaction time and was accompanied by a greater reduction of total scores on the Hamilton Depression Rating Scale−17 items and Hamilton Anxiety Rating Scale compared with escitalopram monotherapy. Conclusions: Patients with MDD showed overall impairments in three domains of attention networks as well as the LMT and a test of subjective alertness. Escitalopram monotherapy significantly improved the LMT scores and the executive control function scores in the ANT at the end of the fourth week of treatment, and the improvement was more extensive with combined escitalopram and agomelatine treatment.

Antidepressant Treatment Strategy with an Early Onset of Action Improves the Clinical Outcome in Patients with Major Depressive Disorder and High Anxiety: a Multicenter and 6-Week Follow-Up Study

A Preliminary Study of Different Treatment Strategies for Anxious Depression.

Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: a real-world study

The Prevalence and Clinical Correlates of Anxiety in Chinese Patients with First-Episode and Drug-Naïve Major Depressive Disorder at Different Ages of Onset

[Repetitive Transcranial Magnetic Stimulation Combined with Antidepressant Medication in Treatment of First-Episode Patients with Major Depression].

Repetitive Transcranial Magnetic Stimulation In Combination With Citalopram In Young Patients With First-Episode Major Depressive Disorder: A Double-Blind, Randomized, Sham-Controlled Trial

Predictors of 4-week antidepressant outcome in patients with first-episode major depressive disorder: An ROC curve analysis

Striatal Functional Connectivity Alterations after Two-Week Antidepressant Treatment Associated to Enduring Clinical Improvement in Major Depressive Disorder

A pilot study on improvements in attention function in major depressive disorder after 12 weeks of escitalopram monotherapy or combined treatment with agomelatine

Effects of Tandospirone Augmentation in Major Depressive Disorder Patients with High Anxiety: A Multicenter, Randomized, Parallel-Controlled, Open-Label Study

Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety.

Use of Mental Health Telemetry to Enhance Identification and Predictive Value of Early Changes During Augmentation Treatment of Major Depression

Early Enhancement of Neuroplasticity Index, the Ratio of Serum Brain-Derived Neurotrophic Factor Level to HAMD-24 Score, in Predicting the Long-Term Antidepressant Efficacy

Effectiveness of mirtazapine as add-on to paroxetine v. paroxetine or mirtazapine monotherapy in patients with major depressive disorder with early non-response to paroxetine: a two-phase, multicentre, randomized, double-blind clinical trial

Control study of mirtazapine and fluoxetine in therapy of depression

Omega-3 Polyunsaturated Fatty Acids Supplementation Alleviate Anxiety Rather Than Depressive Symptoms Among First-Diagnosed, Drug-Naïve Major Depressive Disorder Patients: A Randomized Clinical Trial

Factor analysis of target symptoms of amitriptyline in the treatment of endogenous depression

Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression--The EMC trial

Efficacy of Escitalopram Monotherapy in the Treatment of Major Depressive Disorder

Effect of Electroacupuncture on Therapeutic Effects and Onset Time of Paroxetine for Mild or Moderate Depression Patients

Efficacy of the Integrative Acupuncture and Moxibustion Treatment in Patients With Major Depressive Disorder: The Study Protocol for a Multicenter, Single-Blinded, Randomized Trial in China